MTNB - Earnings call transcript Q1 2018 | Matinas BioPharma Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Matinas BioPharma Quarterly Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jenene Thomas, Investor Relations for Matinas BioPharma. you. Thank

begin. may You

Jenene Thomas

made and the conference for this call to that expectations and that would everyone management's risks may BioPharma hopes, involve These intentions, time, the are quarterly like beliefs, remarks listeners our update and projections remind this thank morning call joining state of you or Matinas I during future. Good uncertainties. webcast. statements At forward-looking

securities could provisions laws. call this made to of are based the Harbor Matinas and federal forward-looking Forward-looking current statements on on These the pursuant are differ statements expectations Safe BioPharma's actual materially. results

a undue reliance As on not statements. you result, should any place forward-looking

periodic could the encourage and the from of by website are Investors documents such Commission. factors that to the filed and these company's on results statements These Exchange in you website. those to Matinas the with and cause reports Some carefully. Exchange are BioPharma Securities contemplated section materially differ available We documents forward-looking the Commission's the in Securities review of actual discussed

company's Following session. opened for be up the will call question-and-answer remarks, a prepared the

the over on Officer now Chief pleasure Jabbour, is Chief the Officer. today Dr. Jabbour. Raphael me Joining Mannino, are and Scientific turn to my to It call Jerry call Jerry Executive

Jerry Jabbour

pleased you on in all laid we during report and Jenene progress two am two good appointed that for dialed you, meaningful almost Thank update clear update we made executing morning those to our In was call. part our I out CEO, the to have call. into months the I March strategy since

important base and frequently more to update shareholder goals although is valued my morning's of One been our connect has brief, one. this an with

our in our dose the development risk, patients comprehensive optimized critical candidate, you demonstrates unmet of a reduce whom platform continues capability MATXXXX where we profile and is delivery of this on patients prioritized work lead successfully by the physicians to are provide solution now very of a leukemia. dose our potentially already having the overall a market and breakthrough resources we statistical ongoing for MATXXXX, which valuable cost and order effectively long this phase potential and phase problems and dose infections treating and product, both evident. study. safety of experience in the by invasive absolutely timeline four lymphoblastic suffering the approval for review prepared of has demonstrate in patients solve. prevention for the also remain the I know development call, term streamlined are program have to today technology, in been designed the that cup which our safety allocating NIH our plan to and the design begun has those of we enrolled of along medical let to potentially safely the of unique formulation medicine, identify undertaken a extremely MATXXX. toxicity safety strategic of an we and lines our of volume having to the continue our characterized to development of These last goal now optimizing disruptive platform associated areas enter clear fungal Alongside technology coffee endpoint confident improved while a optimization is the our for study are and And something our from met the MATXXXX. our need The to We work. garnering each unique success, toward ability tablespoon, and patients, product no overall During excellent despite that formulation in events MATXXXX or from that of now an we with our acute in at to of

begin to through utilization strategic to clear our intention outside of the stated area platform technology our We have expand expectation of is ideal the way collaborations. and the anti-infective that

of third-party capabilities. technology In and relationships important these to help our unique platform bring us data effective, being addition develop cost important our to demonstrating validation to continue

past in molecules there genetics medicine such advancements identifying have XX field the has using power from to disease gradually significant enormous treat shifted the most years, to the of some ways capture and been small solve to to of genes, proteins Over our therapies such health as today through know We RNAs, CRISPR. to gene or potential by plasmids editing gene treat that messenger pathological RNA interfering most challenges. drugs provide expressing genetic therapeutic as DNA or diseases applications, small silencing

are or to LNC can administered in peremptorily. profile apart. a and is dosing think orally molecules A non-toxic companies natural systems that today the molecules required be the effectively ways sophisticated and or has in. technology big, used molecules of improve in great set our hallmark platform uptake our proprietary a inside manner. clinically, exactly for to of lipid a deliver pre-clinical stability that intracellularly we with drugs We animal based to our is potential and our actual us We the data comes in variety be outside and on However stability body way that delivery in execute natural can our where that flexibility focused that genetic order can crystal combined small nano and efficiently know including but all our and believe cellular of

every understanding Our opportunities is the therapy a thinking platform gene no and work messenger these be solution to in that There big. of to DNA that RNA the one of our have systems with potential question our area. From involved are of evaluating plasmids to are delivery the current we CRISPR, indicate we date to areas. research we in limitations delivery in

of value. also creating and the focused we and starting recognize However, and tangible small importance understand

focused plan focus to a it platform that execute the strategic begin our Our to of application in broadening in focused is date manner. space oligonucleotide there and we the to has on been

to and of concept conducting Our in vitro entertain establish platform license a formulating important crystal likely into partners' involve contemplated molecules It strategic studies. proof technology. collaborations our vivo to have nano partners' our and that molecule of will before value with our we in is very and our lipid

will near gene delivery always therapy. step this important we a challenging, we allow first important our to the steps platform need an continue it molecules. we both to This having take, of but to experience, party which as that the viability our first is are represent deal become platform, the and feel with evaluate we third already the area these most to first confident my want In So this the position of in to data in in will have the to do despite first position future. in the collaboration, leader partners first potential be

for medicine. shareholders, building are of ourselves to but innovative and physicians envision value we that of for importantly, an we potential We and part a most its create patients foundation areas significant short the invaluable of solution in company the believe the becoming long term the in has

to this focused question-and-answer execute to to For us, advancing of begins progress trial the what that rapidly Phase our like We as to we on we continuing look our have in you believe back could on session. already I turn the towards during viability pivotal point, would where over and At a we call update with we be demonstrated MATXXXX strategy. our are the technology it for operator our forward patients platform XXXX. X

Operator

Group. is Our first from question Maxim McCarthy Jason of Instructions] coming [Operator

Jason McCarthy

questions. of Couple

for a discuss - using in a been difficulty of that mentioned to sense, approach. on gene terms editing, unique spiral gene crystal cochleates. space, lipid provide the have RNAi in avoid delivery area broad editing the forms able therapy, platform a like in Cochleates question whatever immunogenicity, even the in can in a about you Do how that kind beyond First it's viral very a discuss, to kind be solid we've you get of traps gene Is bit you or a ex there Can using cochleates nucleic can more it you applied Can that little this seen inside. hasn't vivo. bit general. an maybe where for for oligonucleotides you of are in just the nanostructure acids. applications color little immunogenicity, vivo some molecules application and with

Jerry Jabbour

insightful question distinguish other like makes gave we've challenges of different what I'm lipid a XX,XXX the one been Sure. So, why drill And Mannino and happy kind better of of of handle the sitting foot on next no areas. to those Jason, Dr. obviously really delivery? kind of some I down there's lot and that's my for so you've that of some from cochleates remarks. that nano drug during the what view you the challenges question, that in is Raphael really probably to thanks because to there have particles, some seen touched on I'd me in

Raphael Mannino

Thanks, Jason.

you just that things the One out of first immunogenicity. the pointed was

inhibit to calcium. non-immunogenic. nano the a response because lipid made matrix that's immune the of They neither shown, the Our natural is do fundamentally been very of over phospholipid have is crystal years, they and components, response crucial simply very, the stimulate and solid crystals the immune be which nor

the would is response. induce that that about nothing the there so use fundamental And crystal nano lipid immune we

butter refrigerator, is solid to in pointed out, lipids, which as susceptible lipid crystal. butter essentially is a in is attack other with are it's particles, and frying which lipid which which the Secondly, difference liquid. fluid by have the solid the our pan, you crystal contrast, nano This between them, layers in in is and to - most

this layer. other lipid most crystal the It's nano also, multi-layered you of as which so in have And structures, solid. very contrast very, is to said, single

that's both factor put nano shelf solid of is entire an anhydrous stable, So to layers and it's makes the on allow it these which water and multi very crystal, a distinguishing it's crystal, material the another the us in lipid bottle. and very, it crystal anhydrous. no the crystals, There's through

of process of natural a lipid the to material, these particle. body has nano has both in destruction. deliver but this the able oligonucleotides the effects, the again with target again in outside ability, results no compromise for other natural interacts material interior outside oligonucleotides this immunogenicity nanoparticles you only on this which using characteristics particle our in inherent and which it get cell molecules, use degradation the one the and the and is interior the not and then the both two the need involved once to compromising of are toxicity cell interior and of mechanism, particle. the from body into going particle. the things once within And of is membrane designed and is to to constantly the minimize contrast, the mechanism, the and natural in and unnatural the the order delivery toxic is of into aspect the from nano [indiscernible] disrupting delivery with a disrupt to any membranes lipid cell target oligonucleotide very fusion cell crystal for world, immune the ability to cell deliver membrane lipid to uses across membranes key, get fusion, toxicity. So, the cell membrane the and our of along minimize protect from of order no And lipid in fusion the It so oftentimes and particles effectively are protect are cell especially oligonucleotides calcium world oligonucleotide it to the natural classic most to both the responses and In in nano and then into to a be

in a for now animal with And technology forward as worked with so, moving oligonucleotides. we've of long models partners this oligonucleotides into and aggressively looking time to the we along further know, delivery moving delivering are you

Jason McCarthy

leverage XXXX, I think, adoptive pathway, to the back maybe Matinas long my you approval could for can it's that want is walk use important around I'm there's approval? thinking get really a accelerated toxicity, talk so going Jerry, opportunity be to just this bit I it's to docs limited are population the antimicrobial for And follow drug, community, potential a the been an there to potential and the in little remove time, overstated. the and if you LPAD to anti-fungal want Can experience about you pathway to

Jerry Jabbour

spectrum, that have following that was very our Jason not way exactly that in supportive interaction we with obviously learn an at the the there to of that technology and and a we're how and highly willingness work there for that we like Good us safe amphotericin but was broad and that provides very the different question, about meeting push opportunity us we a like drug desire that forward, different come of provides a back believe. one we're toxic our more things here a delivery in works, such behind only was January clear acknowledgement a unique of this FDA to was agency to year, development feeling

medical And for we provided X that clarity reality design is of because why is, this that an the his and of to exactly in much unmet tangible and so in believe the that patients, adaptive flies for like that need phase of to Cornely FDA underlying the agency. that five when more importance FDA all the by speak confidence about Oliver is somebody trial, drug to support of a becomes eyes this the candidate it is minutes

intended, and unmet design and medical position, It's gotten pointed here drugs we we're advantage and that in taking of stage PK that of us and ALL to leukemia framework enroll things. the see a design by in in place do we study, one both want which expertise allow be the to of and and resources study profile foundation somebody really will coming adaptive of allow and date patients to continue really adaptive program, same will analysis to the toward shift put who's year that's meeting pun will just XX the of that design tolerability essentially the and provide the with kind then the the efficacy to ALL time the that So the which the us X Matt and of was go why and need us just no kind would we've using sort out approved, things two the generated team to faster in to typical AML if that this the of and mitigate the that patients, the looks the designed, AML, Wikler take from that the with Phase drop put safety like over that's last patients in interim portion we Phase X believe to see for time. at analysis

for So is protocol exact the development. under still that

statistics will also imagine, As in the trial, can into currently only helping be the very you going the be single controlled successful optimization and is will it we a could but now what placebo right understand FDA but profile what off that we adaptive study. for in year working study, the and with dose us a the believe that take work will the be patients almost implement inclusion if dose in informative to criteria of cut are not on we that selecting from design, should terms better that that really

and pathway. say, of As has go far - seen that seen the as the early some have I existence will of that would mean, that results LPAD process, approval couple the past to mixed while years, that down with kind I for we've in tried we've of, companies be been

opportunity I will package our which framework become until be part next the continued ready think discussions, overall to focus, an profile interaction and demonstrated say we're amphotericin, of could an deliver premature and and opportunity plan we're drug there taking it unmet for different, the we've certainly that's is is medical known safely. our our molecule but efficacy profile but that because the we a need, step, clearly that to to that and given and we can probably has explore. have that we demonstrate There the of a that

Jason McCarthy

be about if space, an a that brief can opportunity maybe [indiscernible] safer. can kids amphotericin it leukemia XX% And rate problem why even for question be adults is little more the upwards I of and the could you one leukemia And speak the these better or and option just Dr. a from with infection bit Mannino, young in - higher. guess

Jerry Jabbour

of Jason, think necessarily uniform to be that of hit and specific putting very fungal are at on being that in growing are in to I'll the risk. and that therapies resistant from incidence more really due different infections handle the actually terms statistical number and today, patients numbers and is creating infections, of kind site is longer see question this Jerry. is I longer that hospital due not tend across to leukemia you've and you neutropenic the periods to those those that's that patients I target. and borne in XX% leukemia infections and mean, board, invasive anywhere XX% the the types used but it's reality more of

is in mentioned, the today which the So XXXX, there certainly patients as ALL growing. of notably is used drug with standard with being prophylax really a be posaconazole, a those probably ALL, the with XXXX of AML which the drug drug the remember, ALL, year can't used the drug vincristine. is care there you opportunity about course entire in $XXX neutropenic which be opportunity patients, of million because to period, ALL globally. XX is in there about to new ASLs, days therapy, it's drug the the and opportunity because to which on would is segment It's interaction cases It and the is And in able side. interaction current

are that Importantly a with posaconazole, likely that resistance increasing to being and area, are is forward care may patients changes segment of treated including though, for that being seeing some and less less in that desirable too, which will posaconazole the be used make new in alternative it of in therapies but to area, take AML how itself. we in physicians coming

about infections are opportunity have a is fungal value alternative a that patients could in the XX%, a no fungal these It's therapy thing able important and is is population but here being in which it obviously the there, XX%, so rate significant, mortality those the has commercial the those is greater the today incidence real a do develop targeting us patient For and of ALL. significant high which a numbers, than infection, of XX%. to of the reality who all is look, development stark of if XX%, course

unmet broad the we from it need here the meet in solution amphotericin an just believe and toxicity we that issue the can from the perfect we're So medical that a profile administration that's really is coming a is and and directions. which drug it's important oral safe at potential, from an spectrum with IV profile efficacy the

on would that's kind look the leukemia overall the of what trial space and So look like. the

Operator

Wainwright. Our Selvaraju is Ram of next question from coming H.C.

Julian Harrison

Ram. for This is on Julian

have track vulvovaginal revisiting off, First you for Is receiving soon. indication curious SCYXXX was status an SCYNEXIS candidiasis. this you fast if I recently just drug, this thoughts any sometime about consider

Jerry Jabbour

happening So that's of obviously, people being of us technology, area into antifungal that It's because the platform our not I ours. of we're our perfect. everything to going after indication of aware in to conducive that's delivery like not action. think SCYNEXIS' of drug the foundation That's is an space, VVC an category, put mechanism regardless focus

- about kind inhibited We invasive are are are of infections, immune of an treating all a condition kind tract cell to by which in fungal the inflammatory system.

safety ours. than perspective, was So the infection. for the going fill MATXXXX drug treatment But taking VVC. study see the SCYNEXIS of and not focus a to non-life for demonstrating down that's to We're lives. more need about we're going mucosal important or was broadest was from happy in path the absorption. a VVC of It We're area it of for an the save the of treatment and candidiasis, threatening spectrum to biggest about focusing never about remember, systemic VVC us vulvovaginal be indicated

Julian Harrison

recent interest on getting line to licensing since reporting indicated it's that been you for Amarin data dyslipidemia. any have XXXX, Regarding Vascepa top close

Jerry Jabbour

superiority in be working reality opportunity the in of discussions I platform the - demonstrates have group expect quarter and interest what that in believe which will believe with drug Amarin yeah, and it create process it let the disruptive ongoing to actually with just could upon thanks that picked for there that being discuss an the that of have outside believe as to a year gets we has position head play third a of though be we to and and asset closer, important out data. I we have we're us not see of that's a head this background, outcomes is as the closer founded, because closer having getting be is, to Vascepa, up their its focus that to company. associated would was goes. but an on ours highlights where for is an opportunity the the we technology, we'll Julian, original to company but reality which continues value this asset that we because

predicated thanks of really nice the event can on creation - is in value this would our but involved focus important in term, we and a the aren't that. on delivery the question. a areas, short technology be add-on, That therapeutic Our but on number ways get for

Operator

thank BioPharma, today. everyone Thank you. Matinas like participating for On behalf of would I to

You time may day. wonderful disconnect have your this and a lines at

Matinas BioPharma (MTNB) 13 May 182018 Q1 Earnings call transcript